Saturday 17 October 2026
Export SVA’s income statement to Excel — free account
Sinovac Biotech, Ltd.
Sinovac Biotech, Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $386.0 million, up 6.82% from fiscal 2024.
6.47
0.00
0.00%
Follow SVA
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | 38.39% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
— | — | — | 4 | |
| 0.00% | 0.00% | 0.00% | 26.39% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 29.88% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 18.22 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(786.38) | (709.59) | (801.49) | 4,708.18 | |
Capital Expenditures |
(196.17) | (455.24) | (860.14) | (860.83) | |
| Other line items | |||||
Cash ROIC |
(6.03%) | (4.24%) | (3.58%) | 20.02% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 10.59 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 1.48 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 4.44 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 227.99 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 50.84 | |
Tax Rate |
— | — | — | (0.20) | |
Research and Development Expense of Revenue |
— | — | — | 6.92% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 14.87% | |
Share Based Compensation of Revenue |
— | — | — | 0.00% | |
Interest Coverage |
— | — | — | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 1.60 | |
Depreciation/Fixed assets |
0.23 | 0.14 | 0.08 | 0.29 | |
Capex/Depreciation |
(1.20) | (3.85) | (12.07) | (2.82) | |
Revenue per Share |
— | — | — | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.09 |
Columns are period end dates